agilon health, inc. (AGL) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $168.00K; Additional Paid in Capital, Common StockUSD $2.14B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $154.00K; Retained Earnings (Accumulated Deficit)USD $-1.91B.
- 2026-03-31: Common Stock, Value, IssuedUSD $166.00K; Additional Paid in Capital, Common StockUSD $2.11B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $479.00K; Retained Earnings (Accumulated Deficit)USD $-1.93B.
- 2025-12-31: Common Stock, Value, IssuedUSD $166.00K; Additional Paid in Capital, Common StockUSD $2.10B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $916.00K; Retained Earnings (Accumulated Deficit)USD $-1.98B.
- 2025-09-30: Common Stock, Value, IssuedUSD $4.15M; Additional Paid in Capital, Common StockUSD $2.09B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $880.00K; Retained Earnings (Accumulated Deficit)USD $-1.79B.
agilon health, inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Noncontrolling Interest, Increase from Sale of Parent Equity Interest USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD | Partners' Capital Account, Public Sale of Units Net of Offering Costs USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $168.00K | $2.14B | $154.00K | $-1.91B | (m) | $227.53M | 3 month · $23.83M 6 month · $30.09M | (m) | (m) | (m) |
| 2026-03-31 | $166.00K | $2.11B | $479.00K | $-1.93B | (m) | $181.43M | 3 month · $6.25M | (m) | (m) | (m) |
| 2025-12-31 | $166.00K | $2.10B | $916.00K | $-1.98B | (m) | $126.73M | 12 month · $49.12M | (m) | (m) | (m) |
| 2025-09-30 | $4.15M | $2.09B | $880.00K | $-1.79B | (m) | $306.08M | 3 month · $7.50M 9 month · $39.60M | (m) | (m) | (m) |
| 2025-06-30 | $4.14M | $2.08B | $787.00K | $-1.68B | (m) | $408.93M | 3 month · $15.38M 6 month · $32.10M | (m) | (m) | (m) |
| 2025-03-31 | $4.13M | $2.07B | $543.00K | $-1.57B | (m) | $500.25M | 3 month · $16.72M | (m) | (m) | (m) |
| 2024-12-31 | $4.12M | $2.05B | $-88.00K | $-1.59B | $470.95M | $470.95M | 12 month · $50.66M | 12 month · $768.00K | (m) | (m) |
| 2024-09-30 | $4.12M | $2.05B | $301.00K | $-1.48B | $574.87M | $574.87M | 3 month · $13.26M 9 month · $48.38M | 3 month · $768.00K 9 month · $768.00K | (m) | (m) |
| 2024-06-30 | $4.11M | $2.04B | $-2.45M | $-1.36B | $676.63M | $675.87M | 3 month · $18.21M 6 month · $35.12M | (m) | (m) | (m) |
| 2024-03-31 | $4.11M | $2.02B | $-2.75M | $-1.33B | $689.27M | $688.49M | 3 month · $16.91M | (m) | (m) | (m) |
| 2023-12-31 | $4.06M | $1.99B | $-2.30M | $-1.33B | $661.84M | $661.02M | 12 month · $69.50M | (m) | (m) | (m) |
| 2023-09-30 | $4.06M | $1.97B | $-6.23M | $-1.10B | $872.37M | $871.60M | 3 month · $20.74M 9 month · $53.98M | (m) | (m) | (m) |
| 2023-06-30 | $4.05M | $1.95B | $-6.37M | $-1.06B | $880.17M | $879.45M | 3 month · $19.57M 6 month · $33.24M | (m) | (m) | (m) |
| 2023-03-31 | $4.14M | $2.13B | $-3.55M | $-1.05B | $1.08B | $1.08B | 3 month · $13.67M | (m) | (m) | (m) |
| 2022-12-31 | $4.12M | $2.11B | $-5.56M | $-1.06B | $1.04B | $1.04B | 12 month · $28.38M | (m) | (m) | (m) |
| 2022-09-30 | $4.12M | $2.09B | $-5.10M | $-1.01B | $1.09B | $1.09B | 3 month · $7.91M 9 month · $18.43M | (m) | (m) | (m) |
| 2022-06-30 | $4.08M | $2.08B | $513.00K | $-977.10M | $1.10B | $1.10B | 3 month · $6.55M 6 month · $10.52M | (m) | (m) | (m) |
| 2022-03-31 | $4.06M | $2.06B | (m) | $-956.45M | $1.11B | $1.11B | 3 month · $3.97M | (m) | (m) | (m) |
| 2021-12-31 | $4.00M | $2.05B | $0.00 | $-957.68M | $1.09B | $1.09B | 12 month · $23.93M | (m) | 12 month · $-309.50M | (m) |
| 2021-09-30 | $3.92M | $2.02B | (m) | $-900.96M | $1.13B | $1.13B | 3 month · $11.96M 9 month · $19.51M | (m) | (m) | 3 month · $104.00K |
| 2021-06-30 | $3.91M | $2.01B | (m) | $-865.11M | $1.15B | $1.15B | 3 month · $6.08M 6 month · $7.55M | (m) | (m) | (m) |
| 2021-03-31 | $2.49M | $265.60M | (m) | $-566.27M | $-298.17M | $-298.24M | 3 month · $1.47M | (m) | (m) | (m) |
| 2020-12-31 | $2.49M | $263.97M | (m) | $-551.19M | $-284.73M | $-284.73M | 12 month · $6.69M | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-262.29M | 3 month · $1.62M 9 month · $4.92M | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-248.28M | 3 month · $2.23M 6 month · $3.30M | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-247.51M | 3 month · $1.07M | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $-232.03M | 12 month · $5.22M | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $41.60M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |